JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation is allowed to use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website for educational purpose only. Bodily introduction of any kind into humans and animals is strictly forbidden by law. This product should only be handled by licenced qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused as a drug, food and cosmetic.
FREE Shipping for orders over $200
Toremifene is a second-generation nonsteroidal selective estrogen receptor modulator (SERM) which has been studied for its effect on the interaction of estrogen receptor isoforms and ligand-related transcriptional regulation. Biologically, it is a chlorinated derivative of tamoxifen (TAM) and is used in research to study binding to the estrogen receptor and possible misfolding due to this ligand, and the positive effect it may have on gene expression with estrogen responsive genes at the molecular level.
Toremifene was identified and developed at the end of the 20th century and has been well reported by pharmacological, biochemical and biological researches. Its role in estrogen receptor signaling networks, nuclear receptor cross-talk, and regulatory influence on the receptor-mediated transcriptional pathways has been studied in experimental studies. At Element CRP, toremifene for sale is supplied exclusively for educational and laboratory research purposes and is not intended for human or animal use, ingestion, or clinical application.
From Pubchem
IUPAC Name:2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamineSynonyms: Acapodene, Farestone, Z-ToremifeneMolecular Formula: C26H28ClNOMolecular Weight: 406.0 g/molCAS Number: 89778-26-7PubChem CID: 3005573
The activity of toremifene has been extensively examined in estrogen receptor–positive assay systems with respect to modulation of receptor-mediated transcription and cellular proliferation pathways. Multiple randomized investigations have characterized its interaction profile relative to structurally related selective estrogen receptor modulators (SERMs), demonstrating comparable estrogen receptor binding with distinct downstream signaling effects. Experimental findings indicate tissue-selective receptor activity and differential regulation of estrogen-responsive genes when compared with tamoxifen.
Toremifene also displays a distinct pharmacokinetic profile relative to other commonly studied SERMs in estrogen signaling research. Unlike tamoxifen, which requires CYP2D6-mediated metabolic activation, toremifene exhibits estrogen receptor activity independent of CYP2D6 biotransformation. Experimental analyses have shown that genetic variation affecting CYP2D6 activity contributes to interindividual response variability, supporting the use of toremifene as a comparator compound for estrogen receptor modulation studies independent of metabolic activation.
Toremifene has been evaluated in controlled preclinical and clinical research frameworks examining estrogen receptor involvement in bone metabolism and skeletal signaling. Investigations have assessed bone mineral density–related parameters under conditions of altered endocrine signaling, identifying receptor-mediated modulation of bone remodeling markers in specific experimental contexts.
Comparative analyses have further explored differences among SERMs in bone-related biochemical markers and site-specific mineral density responses. Head-to-head studies have reported distinct variations between tamoxifen and toremifene, emphasizing tissue-selective estrogen receptor activity rather than uniform skeletal effects.
Toremifene has been examined in androgen-responsive cellular and tissue models to investigate nuclear receptor cross-talk between estrogen and androgen signaling pathways. Experimental studies have evaluated its effects in systems exhibiting dysregulated or pre-neoplastic cellular architecture, focusing on hormone-mediated differentiation and proliferation signaling.
These investigations are intended to provide mechanistic insight into nuclear receptor interactions rather than to support clinical or therapeutic interpretation.
Research examining toremifene has documented its interaction with lipid metabolism pathways through estrogen receptor–mediated regulatory mechanisms. Controlled experimental analyses have evaluated changes in lipid-associated biomarkers, including cholesterol transport and lipid homeostasis signaling cascades.
Additional studies conducted in hormone-modulated research environments have reported alterations in lipid-related parameters, supporting the role of estrogen receptor signaling in metabolic regulation at the molecular level. These findings are utilized for mechanistic evaluation rather than outcome-based interpretation.
Toremifene is a chlorinated, non-steroidal selective estrogen receptor modulator (SERM) extensively investigated for its receptor binding characteristics, tissue selectivity, and metabolic independence from CYP2D6-mediated activation. Research has examined its involvement in estrogen receptor signaling, skeletal biology, androgen-sensitive tissue models, and lipid metabolism pathways.
Toremifene for sale by Element CRP is intended strictly for laboratory, analytical, and educational research purposes and is not approved for human or animal consumption, ingestion, or clinical use. Buy Toremifene if you are a licensed researcher.
Toremifene Citrate is a small-molecule triphenylethylene SERM structurally related to Tamoxifen, featuring chlorination differences that influence binding kinetics and tissue-selective profile. The compound supports reliable behaviour in cell-based estrogen receptor pharmacology research applications.
Cell-based research with Toremifene examines ER-alpha and ER-beta binding affinity, ligand-induced conformational changes, and tissue-selective transcriptional responses in MCF-7, T-47D, and other ER-positive cell line models. Comparative SERM pharmacology positions Toremifene alongside Tamoxifen and Clomiphene for selectivity mapping.
Element CRP supplies this product at 60mg/mL × 30mL. USA-manufactured via chemical synthesis and verified at 99%+ purity by HPLC and Mass Spectrometry. Pre-mixed liquid solution in 30mL or 60mL bottle with dropper; ready for laboratory use. Store at 15-25°C, away from direct light.
WARNING: For research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease. For use by qualified research professionals only.
Forgot password?
Country: United States (US-only registration)
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
Element CRP is a chemical supplier. Element CRP is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. Element CRP is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
